Atomo Diagnostics Ltd

Chart & performance

D1W1MN

P/E

—

P/S

3.05

EPS

—

Div yield, %

—

Shrs. gr., 5y

7.95%

Rev. gr., 5y

-4.50%

Revenues

+40.65%

Net income

-4m

L-29.32%

CFO

-3m

L+71.94%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various applications, including COVID-19 detection, HIV screening, pregnancy confirmation, and assessing respiratory conditions.

Key people

Byron Darroch

General Manager- Operations

Hans Fredman

Chief Commercial Officer

Robert Snoch

Group Financial Controller

John Kelly

Chief Executive Officer, Founder

URL

https://www.atomodiagnostics.com/

IPO date

Apr 16, 2020

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2026‑06	2025‑06	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06	2017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT